Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $9

Author: Benzinga Newsdesk | January 16, 2024 11:37am

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from $10 to $9.

Posted In: MCRB